Transdermal buprenorphine in cancer pain and palliative care

Abstract

Transdermal buprenorphine has been assessed as a therapy for chronic cancer and non-cancer pain in both clinical and postmarketing surveillance studies. Data from 239 patients who had participated in a follow-up study of up to six years have shown efficacy and safety, and good tolerability over prolonged treatment periods with a marked stability of doses. From the cancer pain population (134 patients), 20% stayed on transdermal buprenorphine until the end of their lives. Postmarketing surveillance study data from 13 179 patients, including 3690 cancer patients assessed during a 10-week observation period, showed that 81% of patients achieved good/very good pain relief with transdermal buprenorphine. Furthermore, 49.6% of patients did not require any analgesic comedication or rescue therapy, a point that is particularly important in the elderly population. Results from the Spanish Pain Society on transdermal buprenorphine in chronic non-cancer, neuropathic and cancer-related pain, and on switching from morphine, also confirmed its beneficial efficacy and safety, and showed that buprenorphine does not antagonize pain relief, or cause withdrawal when combined with full μ-agonists. The effectiveness of buprenorphine is further supported by evidence of its pronounced anti-hyperalgesic effect in a human pain model, which may be a factor in explaining the efficacy of buprenorphine in neuropathic pain. When switching of opioids is indicated to improve pain relief or reduce adverse events, equipotency dosage ratios are important. The equipotency ratio for morphine to buprenorphine, previously established as 75:1, is now being questioned as new data from a retrospective cohort study were published indicating a ratio of 100:1. Moreover, transdermal buprenorphine has superior safety in respect to respiratory depression, immunological and renal effects compared with standard World Health Organization step III opioids, which makes it highly suitable for treating moderate-to-severe pain also in cancer patients, a per se vulnerable patient population requiring a sensible selection of potent analgesics.

Keywords

analgesia antihyperalgesia buprenorphine cancer pain neuropathic pain opioid palliative care switching transdermal

Get full access to this article

View all access options for this article.

References

Griessinger N

Sittl R

Likar R.

Transdermal buprenorphine in clinical practice - a post-marketing surveillance study in 13179 patients. Curr Med Res Opin2005; 21: 1147-1156.

Böhme K

Likar R.

Efficacy and tolerability of a new opioid analgesic formulation, buprenorphine transdermal therapeutic system (TDS), in the treatment of patients with chronic pain: a randomised, double-blind, placebo-controlled study. Pain Clinic2003; 15: 193-202.

Sorge J

Sittl R.

Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multi-center, randomized, double-blind, placebo-controlled study. Clin Ther2004; 26: 1808-1819.

Sittl R

Griessinger N

and

Likar R.

Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther2003; 25: 150-168.

Likar R

Kayser H

Sittl R.

Transdermal buprenorphine for long-term management of chronic cancer and non-cancer pain. Results of an open-label, multicentre, follow-up study. Book of Abstracts, International Forum on Pain Medicine. Sofia, 2005.

Muriel C

, and the

Opioid Study Group of the Spanish Pain Society

. Assessment of the transdermal buprenorphine patch in patients with cancer pain. Rev Soc Esp Dolor2004; 11: 41-48.

Mystakidou K

Parpa E

Tsilika E

et al.

Long-term management of noncancer pain with transdermal therapeutic system-fentanyl. J Pain2003; 4: 298-306.

Nugent M

Davis C

Brooks D

et al.

Long-term observations of patients receiving transdermal fentanyl after a randomized trial. J Pain Symptom Manage2001; 21: 385-391.

Hanks GW

De Conno F

Cherny N

et al.

;

Expert Working Group of the Research Network of the European Association for Palliative Care

. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer2001; 84: 587-593.

10.

Christoph T

Kögel B

Schiene K

et al.

Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain. Eur J Pharmacol2005; 507: 87-98.

11.

Likar R

Sittl R.

Transdermal buprenorphine for treating nociceptive and neuropathic pain: four case studies. Anesth Analg2005; 100: 781-785.

12.

Rodriguez MJ

and the

Opioid Study Group of the Spanish Pain Society

. Transdermal buprenorphine in neuropathic pain. Rev Soc Esp Dolor2004; Suppl 5: 11-21.

13.

Koppert W

Ihmsen H

Körber N

et al.

Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model. Pain2005; 118: 15-22.

14.

Angst MS

Koppert W

Pahl I

et al.

Short-term infusion of the m-opioid agonist remifentanil in humans causes hyperalgesia during withdrawal. Pain2003; 106: 49-57.

15.

Celerier E

Laulin JP

Larcher A

et al.

Long-lasting hyperalgesia induced by fentanyl in rats: preventive effect of ketamine. Anesthesiology2000; 92: 465-472.

16.

Guignard F

Chauvin M

Miller JC

et al.

Acute opioid tolerance: intraoperative remifentanil increases postoperative pain and morphine requirement. Anesthesiology2000; 93: 409-417.

17.

Simonnet G.

Opioids: from analgesia to anti-hyperalgesia? Editorial. Pain2005; 118: 1-2.

18.

Tröster A

Sittl R

Singler B

et al.

Quantification of analgesic and antihyperalgesic effects of buprenorphine and fentanyl in healthy volunteers. Book of Abstracts, 3rd World Congress of the World Institute Of Pain, Barcelona, 2004: 74-74.

19.

Sittl R

Likar R

Poulsen Nautrup B.

Equipotent doses of transdermal fentanyl and buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study. Clin Ther2005; 27: 225-237.